Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | midodrine | 4195 | drug-path |
| Primary immunodeficiency | R-HSA-5601905 | map05340 | midodrine | 4195 | drug-path |
| Melanogenesis | R-HSA-5662702 | map04916 | midodrine | 4195 | drug-path |
| Wnt signaling pathway | R-HSA-195721 | map04310 | midodrine | 4195 | drug-path |
| Shigellosis | 0 | map05131 | midodrine | 4195 | drug-path |
| T cell receptor signaling pathway | R-HSA-983705 | map04660 | midodrine | 4195 | drug-path |
| Insulin signaling pathway | R-HSA-74752 | map04910 | midodrine | 4195 | drug-path |
| Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | midodrine | 4195 | drug-path |
| Amyotrophic lateral sclerosis (ALS) | Q8NDH6-2 | 0 | midodrine | 4195 | drug-path |
| Apoptosis | R-HSA-109581 | map04210 | midodrine | 4195 | drug-path |
| Hedgehog signaling pathway | R-HSA-5358351 | map04340 | midodrine | 4195 | drug-path |
| VEGF signaling pathway | R-HSA-194138 | map04370 | midodrine | 4195 | drug-path |
| Long-term potentiation | R-HSA-9620244 | map04720 | midodrine | 4195 | drug-path |
| Vibrio cholerae infection | R-HSA-9609646 | map05110 | midodrine | 4195 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | midodrine | 4195 | drug-path |
| Gap junction | R-HSA-190861 | map04540 | midodrine | 4195 | drug-path |
| GnRH signaling pathway | R-HSA-168638 | map04912 | midodrine | 4195 | drug-path |
| Vascular smooth muscle contraction | R-HSA-445355 | map04270 | midodrine | 4195 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | ranitidine | 3001055 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | ranitidine | 3001055 | drug-path |